大分割三维适形放疗联合化疗治疗中晚期肝癌45例疗效分析
Effect Analysis of Hyper-fractionated Three-Dimensional Conformal Radiotherapy Combined with Chemotherapy for Advanced Liver Carcinoma
-
摘要: 目的 探讨大分割三维适形放射治疗联合化疗治疗中晚期肝癌的疗效。 方法 对45例不能手术的中晚期肝癌患者进行介入治疗两次, 其中22例结合大分割三维适形放射治疗, 采用6MV X线, 单剂量为3~5Gy, 隔日1次,总剂量为DT 45～55Gy 23例单纯介入治疗。 结果 大分割三维适形放疗联合介入治疗组近期有效率(CR+PR)为85.7%,对照组为52.3%,两组差异有统计学意义；1、2、3年的生存率联合治疗组为68.7%,56.8%, 39.8%,对照组为51.2%, 28.7%, 15.7%,两者差异有统计学意义。两组间不良反应差异无统计学意义(P>0.05）。 结论 对于不能手术切除的中晚期肝癌患者, 大分割3DCRT结合TACE有较好的疗效，不良反应可以耐受。Abstract: Objective To analysis the effect of hyperfractionated three-dimensional conformal radiotherapy (HF-3DCRT) combined with transarterial chemoembolization (TACE) for advanced liver carcinoma. Methods Total of 45 patients with unresectable advanced liver carcinoma were randomly devided into two groups: 22 patients were treated with HF-3DCRT plus TACE and the rest 23 patients were treated with TACE alone. TACE were treated with 2 sessions in either group. For HF-3DCRT, radiation was provided by 6MV X ray, patients received a total dose of 45~55Gy(3~5Gy per session) every other day. Results The survival rates of HF-3DCRT plus TACE group in the 1st, 2ed and 3rd year were 68.7%, 56.8%and 39.8%; 51.2%, 28.7% and 15.7%, respectively, in the TACE group. The difference between the two groups was significant. The response rates (CR+PR) of HF-3DCRT plus TACE group and TACE alone group were 85.7% and 52.3%, the difference was statistically significant difference. There was no difference of side-effect between the two groups (P>0.05). Conclusion Hyperfractionated three-dimensional conformal radiotherapy plus transarterial chemoembolizaton is effective for the treatment of advanced liver carcinoma and the patients can tolerate the side-effects.
下载:
